Heron Therapeutics Inc. (HRTX)
1.72
0.03 (1.78%)
At close: Feb 20, 2025, 3:59 PM
1.68
-2.04%
After-hours: Feb 20, 2025, 05:45 PM EST
undefined% (undefined)
| Bid | 1.67 |
| Market Cap | 260.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | -10.72 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.73 |
| Volume | 964,753 |
| Avg. Volume (20D) | 2,976,255 |
| Open | 1.71 |
| Previous Close | 1.69 |
| Day's Range | 1.68 - 1.74 |
| 52-Week Range | 1.04 - 3.93 |
| Beta | undefined |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 1987
Employees 126
Stock Exchange NASDAQ
Ticker Symbol HRTX
Website https://www.herontx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 249.85% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Heron Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+38.98%
Heron Therapeutics shares are trading higher. Need...
Unlock content with
Pro Subscription
3 months ago
-30.43%
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and narrowed its FY24 product revenue guidance.
